Literature DB >> 30045934

Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.

Ronald A Lubet1, Vernon E Steele1, Robert H Shoemaker1, Clinton J Grubbs2.   

Abstract

Because of the importance of testing reproducibility of results, we present our findings regarding screening agents in preclinical chemoprevention studies in rodent models performed by the Chemopreventive Agent Development Research Group (CADRG) of the Division of Cancer Prevention of the NCI. These studies were performed via contracts to various commercial and academic laboratories. Primarily, results with positive agents are reported because positive agents may progress to the clinics. In testing reproducibility, a limited number of direct repeats of our standard screening assays were performed; which entailed initiating treatment shortly after carcinogen administration or in young transgenic mice and continuing treatment until the end of the study. However, three additional protocols were employed relating to reproducibility: (i) testing agents at lower doses to determine efficacy and reduced toxicity; (ii) testing agents later in tumor progression when microscopic lesions existed and, (iii) testing multiple agents of the same mechanistic class. Data with six models that were routinely employed are presented: MNU-induced ER-positive mammary cancer in rats; MMTV-Neu ER-negative mammary cancers in transgenic mice; AOM-induced colon tumors in rats; intestinal adenomas in Min mice; OH-BBN-induced invasive rat urinary bladder cancers in rats; and UV-induced skin squamous carcinomas in mice. It was found that strongly positive results were highly reproducible in the preclinical models evaluated. Cancer Prev Res; 11(10); 595-606. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30045934      PMCID: PMC6186395          DOI: 10.1158/1940-6207.CAPR-18-0084

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  57 in total

1.  The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin.

Authors:  Guobin He; Stephanie Muga; Philippe Thuillier; Ronald A Lubet; Susan M Fischer
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

2.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

Authors:  Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janine L Mansi; Dharsha Shivapatham; Sami Shousha; Jie Jiang; David Peston; Nigel Barrett; David Vigushin; Ken Morrison; Emma Beresford; Simak Ali; Martin J Slade; R Charles Coombes
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

3.  Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Authors:  Peter T Vedell; Yan Lu; Clinton J Grubbs; Yuxin Yin; Hui Jiang; Kirby I Bland; Donald D Muccio; Dusica Cvetkovic; Ming You; Ronald Lubet
Journal:  Mol Pharmacol       Date:  2013-01-04       Impact factor: 4.436

4.  The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.

Authors:  N N Mahmoud; S K Boolbol; A J Dannenberg; J R Mestre; R T Bilinski; C Martucci; H L Newmark; A Chadburn; M M Bertagnolli
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

5.  Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

Authors:  E D Bischoff; M M Gottardis; T E Moon; R A Heyman; W W Lamph
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

6.  Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.

Authors:  Kendall Wu; Hee-Tae Kim; Jenny L Rodriquez; Susan G Hilsenbeck; Syed K Mohsin; Xiao-Chun Xu; William W Lamph; John G Kuhn; Jeff E Green; Powel H Brown
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-05       Impact factor: 4.254

7.  Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.

Authors:  R F Jacoby; C E Cole; K Tutsch; M A Newton; G Kelloff; E T Hawk; R A Lubet
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

8.  Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

Authors:  Chunhua Lu; Corey Speers; Yun Zhang; Xiaochun Xu; Jamal Hill; Emily Steinbis; Joseph Celestino; Qiang Shen; Heetae Kim; Susan Hilsenbeck; Syed K Mohsin; Alan Wakeling; C Kent Osborne; Powel H Brown
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

9.  Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

Authors:  M M Gottardis; V C Jordan
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

10.  Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Authors:  Craig A Elmets; Jaye L Viner; Alice P Pentland; Wendy Cantrell; Hui-Yi Lin; Howard Bailey; Sewon Kang; Kenneth G Linden; Michael Heffernan; Madeleine Duvic; Ellen Richmond; Boni E Elewski; Asad Umar; Walter Bell; Gary B Gordon
Journal:  J Natl Cancer Inst       Date:  2010-11-29       Impact factor: 13.506

View more
  1 in total

1.  Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers.

Authors:  Ronald A Lubet; Brandy M Heckman-Stoddard; Jennifer T Fox; Fariba Moeinpour; M Margaret Juliana; Robert H Shoemaker; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2019-12-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.